The success of the Polio Eradication Initiative promises to bring the world the benefits of sustained improvements in quality of life (i.e., cases of paralysis and deaths avoided) and saved costs from cessation of vaccination. Obtaining these benefits requires that policy makers manage both the transition from the current massive use of oral polio vaccine (OPV) to a world without OPV and the risks of potential future reintroductions of polioviruses. In 2001, we began a case study on retrospective polio risk management to demonstrate the importance of using a dynamic disease model to correctly estimate the cost-effectiveness of vaccines. Discussions with the CDC about the case study led to an opportunity for us to develop a large model to support the prospective decision making process. This paper tells the story of our journey, emphasizing insights about the requirements for analysts to create tools that really help high-level decision makers.

This is the whole item.

Date created

• 2005 July 17-2005 July 21

Type

• Document

Processing Activity

• Processing documentation available at: https://wiki.albany.edu/display/SCA/Processing+Ingested+Digital+Files

License

• Creative Commons BY-NC-ND Attribution-NonCommercial-NoDerivs 4.0 International

  
  Contact Us for questions or additional rights.

ITEM CONTEXT

Part of

cc5bb0ac12a5b68b26b1583548898dae

Scope and Contents

Part of

3c582e6f5cf305ef0030c7471b499022

Scope and Contents

Part of

23d738ba88f8333bc39725f9cb5bd0b8

Scope and Contents

Collection

System Dynamic Society Records

Scope and Contents

Collecting area

• This collection is part of the University Archives